Form 4: Blend Labs Head of Revenue, Brian Kneafsey, Sells 30,000 Shares Under 10b5-1 Plan
SEC Form 4 Filing
Brian Kneafsey, Head of Revenue at Blend Labs, sold 30,000 shares of Class A Common Stock at an average price of $3.5899 on January 21, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- On January 21, 2025, Brian Kneafsey, the Head of Revenue at Blend Labs, sold 30,000 shares of Class A Common Stock.
- The sale was executed at a weighted average price of $3.5899 per share.
- The shares were sold under a Rule 10b5-1 trading plan adopted on September 12, 2024.
- Following the transaction, Kneafsey directly owns 806,759 shares of Blend Labs' Class A Common Stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the sale was conducted under a pre-arranged 10b5-1 trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.
Industry Context
Insider sales are a common occurrence, and the use of a 10b5-1 plan suggests the sale was pre-planned and not based on any specific non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under 10b5-1 plans are generally viewed as less informative.
Stakeholder Impact
- The sale of shares by a company executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 09/12/2024 | Date the Reporting Person adopted a Rule 10b5-1 trading plan |
| 01/21/2025 | Date of the transaction (sale of shares) |
| 01/23/2025 | Date of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.